Stephen Aselage

Patara Pharma LLC provides biotechnology solutions. It develops biopharmaceutical therapy for the treatment of allergic and inflammatory diseases and conditions that affect orphan patient populations. The company was founded by William Gerhart, Pravin Soni and Ahmet Tutuncu in 2013 and is headquartered in San Diego, CA.

Acer Therapeutics, Inc. develops therapeutics for the treatment of orphan diseases. Its current pipeline consists of two late-stage clinical products: ACER-002 for vascular Ehlers-Danlos Syndrome (vEDS), and ACER-001 for Maple Syrup Urine Disease (MSUD). The company was founded by Chris Schelling and is headquartered in Cambridge, MA.

Desert Gateway, Inc. operates as a capital pool company. It is presently a development stage company seeking a potential acquisition of or merger with a yet to be identified business opportunity. The company was founded on February 8, 2008 and is headquartered in Bartlesville, OK.

Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX.

Retrophin, Inc. provides biotechnology services. It is a biotechnology company dedicated to developing drugs for rare and life-threatening diseases. The company was founded in 2011 and is headquartered in New York, NY.

Acuitas Therapeutics is a private biotechnology company based in Vancouver, Canada that specializes in developing delivery systems for nucleic acid therapeutics based on lipid nanoparticles. The Canadian company partners with pharmaceutical and biotechnology companies, academic institutes, and non-governmental organizations to advance nucleic acid therapeutics into clinical trials and the marketplace. Acuitas Therapeutics has agreements in place with several partners to use its proprietary lipid nanotechnology in the development of COVID-19 vaccines, including Pfizer/BioNTech for Comirnaty®. The CEO of the company is Thomas Madden.

Kyalin Biosciences, Inc. manufactures biopharmaceutical products. The firm develops an intranasal delivery form of carbetocin, which is a synthetic version of the natural occurring peptide hormone, oxytocin, for the treatment of core deficits that characterize the autistic spectrum disorders. The company was founded by Srinivas G. Rao and is headquartered in San Diego, CA.

Acer Therapeutics, Inc. is a pharmaceutical company, which engages in the acquisition, development, and commercialization of therapies for medical needs. Its product pipeline includes Olpruva, Edsivo, and ACER-801. Olpruva is used for the treatment of urea cycle disorders. Edsivo is a type of celiprolol used in treating Vascular Ehlers-Danlos syndrome. ACER-001 treats menopausal related Vasomotor symptoms. The company was founded by Chris Schelling on March 15, 1991 and is headquartered in Newton, MA.